false 0001922335 0001922335 2024-06-18 2024-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 18, 2024

 

SYRA HEALTH CORP.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41822   85-4027995
(State or other jurisdiction   (Commission   (I. R. S. Employer
of incorporation)   File Number)   Identification No.)

 

1119 Keystone Way N. #201

Carmel, IN 46032

(Address of principal executive offices, including zip code)

 

(463) 345-8950

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Class A Common Stock, $0.001 par value   SYRA   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

On June 18, 2024, Syra Health Corp. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). A total of 15,222,830 shares of common stock (including 833,334 shares of Class B common stock with each share of Class B common stock having 16.5 votes per share) , constituting a quorum, were represented in person or by valid proxies at the Annual Meeting. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting, as set forth in the Definitive Proxy Statement, filed with the Securities and Exchange Commission on April 24, 2024 are as follows:

 

Proposal 1. All of the eight (8) nominees for director were elected to serve until the 2025 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director’s earlier resignation, removal or death. The result of the votes to elect the eight (8) directors was as follows:

 

Directors   For   Against   Abstain   Broker Non Vote
Sandeep Allam   14,122,315   0   18,481   1,082,034
Dr. Andrew M. Dahlem   14,121,873   0   18,923   1,082,034
Dr. Ketan Paranjape   14,122,273   0   18,523   1,082,034
Dr. Vijayapal R. Reddy   14,122,158   0   18,638   1,082,034
Dr. Avutu S. Reddy   14,121,543   0   19,253   1,082,034
Sherron Rogers   14,122,452   0   18,344   1,082,034
Dr. Deepika Vuppalanchi   14,121,708   0   19,088   1,082,034
Priya Prasad   14,122,158   0   18,638   1,082,034

 

Proposal 2. The appointment of M&K CPAs, PLLC, as the Company’s independent registered public accounting firm for its fiscal year ended December 31, 2024 was ratified and approved by the stockholders by the votes set forth in the table below:

 

For   Against   Abstain   Broker Non Vote
15,201,965   9,025   11,840   0

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SYRA HEALTH CORP.
     
Date: June 18, 2024 By: /s/ Deepika Vuppalanchi
   

Deepika Vuppalanchi

Chief Executive Officer

 

 

v3.24.1.1.u2
Cover
Jun. 18, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 18, 2024
Entity File Number 001-41822
Entity Registrant Name SYRA HEALTH CORP.
Entity Central Index Key 0001922335
Entity Tax Identification Number 85-4027995
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1119 Keystone Way N. #201
Entity Address, City or Town Carmel
Entity Address, State or Province IN
Entity Address, Postal Zip Code 46032
City Area Code (463)
Local Phone Number 345-8950
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A Common Stock, $0.001 par value
Trading Symbol SYRA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Grafico Azioni Syra Health (NASDAQ:SYRA)
Storico
Da Ott 2024 a Nov 2024 Clicca qui per i Grafici di Syra Health
Grafico Azioni Syra Health (NASDAQ:SYRA)
Storico
Da Nov 2023 a Nov 2024 Clicca qui per i Grafici di Syra Health